You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: NINDS

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Ovarian cancer using novel nanoparticle formulations

    SBC: KIROMIC BIOPHARMA INC            Topic: 102

    DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Production of High Specific Activity Lutetium-177

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A separation method will be tested and evaluated to determine the feasibility of providing no carrier added lutetium-177 (Lu-177) for use in radiotherapeutic applications. An indirect method will be used to produce Lu-177 (neutron capture followed by decay). Separation of the Lu-177 from the target material will enable us to provide carrier-free Lu-177 suita ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Nanostructured Calcium Phosphate for Gene Delivery to Bone

    SBC: Angstrom Medica, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoporosis is a major and growing health care problem that responds inadequately to standard pharmacologic therapy. Because of its low bone mineral density, osteoporotic bone is mechanically weak and fractures more easily than normal bone. Moreover, fracture repair is compromised in osteoporotic patients. The work described in this Phase I STTR proposal aims ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Design of an Automated Psoriasis Treatment System

    SBC: Boston Array Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Up to 3 percent of populations worldwide have psoriasis. A large number of the patients with psoriasis can be treated using UV light exposure. We propose to employ a light modulating microchip based on recent Micro Electro Mechanical Systems (MEMS) technological developments to build an Automated Psoriasis Treatment System. The overall goal of Phase I a ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. ADULT HUMAN PROGENITOR CELLS FOR CARDIAC REGENERATION

    SBC: KARDIA THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ability to create new cardiac tissue using progenitor cells via engraftment would be a significant advance. However, the existing types of progenitor cells presently in Phase I clinical trials face significant limitations, including lack of evidence that the donor cells (1) produce new cardiac myocytes, versus creating benefits via neoangiogenesis or ventr ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Use of Self-Assembled Crystals in Cyanide Detection

    SBC: CHEMMOTIF, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): ChemMotif, Inc. is developing a range of sophisticated test strips that are reliable and sufficiently sensitive to be useful in public health, environmental, and homeland security applications. The objective of this proposal is the development of an improved analytical test strip for the determination of cyanide in water at or below EPA actionable levels (0. ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government